Between the Lines

Expert perspectives on a recent clinical trial readout indirectly comparing acalabrutinib and zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Expert hematologist-oncologists review data from the MajesTEC-1 trial and discuss the optimal management of cytokine release syndrome in patients on therapy for relapsed/refractory multiple myeloma.

Key opinion leaders review recent data from the ASCO 2023 annual meeting surrounding the MonumenTAL-1 and RedirecTT-1 trials, considering their impact on the real-world management of relapsed/refractory multiple myeloma.

Toni Choueiri, MD, and Rohit Gosain, MD present 3-year follow-up data from the CheckMate 9ER trial, discussing a variety of outcomes concerning the use of nivolumab plus cabozantinib in patients with advanced renal cell carcinoma, and sharing clinical insights for community oncologists.

Joshua K. Sabari, MD, and Helena A. Yu, MD, discuss the evolving treatment landscape in non–small cell lung cancer for patients with EGFR exon 20 insertion mutations and results from a real-world study that may impact the field.

Nelson J. Chao, MD, MBA, and Michael Grunwald, MD review Acute Graft-Versus-Host Disease diagnosis and treatment before engaging with two REACH2 trial post hoc analyses, sharing clinical implications and key takeaways.

Expert hematologist-oncologists Thomas Leblanc, MD, and Bhumika Patel, MD, review clinical data behind the long-term use of tagraxofusp and share their own experience.

Expert oncologists Aditya Bardia, MD, MPH, and Alison Conlin, MD, review clinical data behind the use of sacituzumab govitecan in metastatic TNBC from the phase 3 ASCENT study.

Martin Dietrich, MD, PhD, Sara Tolaney, MD, MPH, and Gregory Vidal, MD, PhD review recent data from the TROPiCS-02 trial on sacituzumab govitecan and discuss the clinical implications of these findings.

Dr. Joseph Mikhael and Dr. Hakan Kaya review key efficacy and safety data for the combination of Selinexor, Carfilzomib and Dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.

Dr Joshua Richter and Dr Peter Forsberg review key trial data and dosing strategies for selinexor based combinations.

Expert hematologist-oncologists share insight on the E7438-G000-101 clinical trial and consider use of tazemetostat, an EZH2 inhibitor, in relapsed/refractory follicular lymphoma.

Expert oncologists review key data from the CRESTONE trial, which observed the safety and efficacy of seribantumab, an anti-HER3 IgG2 monoclonal antibody, in solid tumors with NRG1 fusions.

Shilpa Gupta, MD, and Vinit Makkar, MD, discuss the treatment patterns and disease management of locally advanced/metastatic urothelial carcinoma, with a focus on data from the US physician-based PARADIGM study.

Michael R. Bishop, MD, and Bruce B. Bank, MD, review results from the ELEVATE-RR noninferiority trial on acalabrutinib versus ibrutinib in CLL, and discuss the clinical implications of the findings.

Stacy A. Cohen, MD, and Mark Lewis, MD review results from the GALAXY study on circulating tumor DNA dynamics in CRC that were recently presented at ASCO GI 2022, and discuss the clinical implications of the findings.

Expert perspectives on recent updates in the use of proteasome inhibitors for patients with multiple myeloma.

A panel of oncologists reviews a publication by Motzer et al. (2021) on data from the CLEAR trial studying lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma treatment and discuss the clinical implications of the results.

Expert oncologists review safety/efficacy data behind mobocertinib, a small molecule tyrosine kinase inhibitor, in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.

Suzanne Fanning, DO, and Joshua Richter, MD, discuss clinical implications of a real-world study of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Neeraj Agarwal, MD, and Simon Chowdhury, MD, review final results from the TITAN study of apalutamide in patients with mCSPC and discuss the clinical implications of the findings.

Experts discuss use of ponatinib in chronic myeloid leukemia and optimal dosing.

Daniel Petrylak, MD and Donald Barry Boyd, MD, MS review a publication presenting use of avelumab maintenance in patients with locally advanced or metastatic urothelial carcinoma in real-world practice and discuss their own experiences with the regimen.

Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the article, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Pernthaler B, et al.

Drs. Gupta and Brown discuss a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.

Lyudmila Bazhenova, MD, and Frederico Albrecht, MD, consider when to refer to a clinical trial data and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer based on a recent publication by Bassel Nazha, MD, MPH.

Key takeaways from a recent study of tipifarnib as treatment for recurrent and/or metastatic mHRAS head and neck squamous cell carcinoma.

Experts collaborate to share and reflect on data from an eNRGy1 global registry study, which analyzed therapy in NRG1 fusion–driven lung cancers.

Drs Liliana Bustamante and Richard Kim review “Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases,” and consider how to apply the paper’s findings into clinical practice.

Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, provide insight on the results and clinical implications of the EMPIRE-1 trial in prostate cancer.